Data in a Phase 3 Study of First-Line Brigatinib vs. Crizotinib in NSCLC (ALTA-1L)
Dr. Mohammed Jahanzeb, MD provides Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs. Crizotinib in NSCLC (ALTA-1L).
Related Articles
Breast Cancer Genetic Testing – Should Doctors Use ctDNA? Nathalie McDowell Johnson, MD
Dr. Nathalie M. Johnson, MD, discusses the importance of adopting ctDNA testing in breast cancer management. Find out how it can benefit patients with high-risk…
FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy
Exciting news in endometrial cancer treatment: FDA approves dostarlimab-gxly for broader patient population. Learn about the clinical trial and its positive results.
90% Patients Unaware Of Simple Genetic Test for Cancer – Kevin Hughes, MD
Discover the problem of underutilization of genetic testing in cancer. Find out how it can lead to missed opportunities for early intervention.
FDA Accelerates Approval of Afamitresgene Autoleucel for Advanced Synovial Sarcoma
Introduction On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (TECELRA) for treating adults with unresectable or metastatic synovial sarcoma. This approval…
FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy
Exciting news in endometrial cancer treatment: FDA approves dostarlimab-gxly for broader patient population. Learn about the clinical trial and its positive results.
Genetic Testing Cancer, Practice Changing? – Dr. Erica Giblin, MD
Discover the potential of ctDNA monitoring in revolutionizing cancer treatment. Genetic testing advancements offer new insights into cancer recurrence detection.
Small Cell Lung Cancer Treatment – Dr. Jacob Sands, MD
Learn about the latest advancements in small cell lung cancer treatment and discover effective treatment options for this aggressive form of cancer.
Blood Test For Cancer Markers in Breast Cancer – Dr. Barry Rosen, MD
Learn about ctDNA testing for cancer markers and its potential impact on treatment decisions. Explore the insights shared by Dr. Barry Rosen in this informative…
Hagop Kantarjian: Only 9 Free Seats | 33 Top Hem KOLs, La Jolla AML-ALL
We are excited to extend a special discounted invitation for the next 9 hematologists to register for the upcoming AML-ALL Meeting in La Jolla, CA…
ASCO 2024: Phase 3 IMROZ Study: Sarclisa (Isatuximab) + VRd in Transplant-Ineligible NDMM Patients
Explore the longer treatment duration and consistent benefits of Sarclisa in patients with multiple myeloma who are ineligible for transplant.